Cynata Therapeutics Ltd has released a press release.
Potential Utility of Cymerus MSCs in Heart Attack Model
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
- Cymerus MSCs Effective in Preclinical Lung Disease Study
- Patient Enrolment Opens in COVID-19 Clinical Trial
- Cynata Appoints Dr Geoff Brooke as Chairman
- Cynata Announces Positive Results from GvHD Trial Follow-up
Later from Cynata Therapeutics
- Phase 3 Osteoarthritis Clinical Trial Commences
- CYP Closes $15m Institutional Placement to Expand Pipeline
- Investor Presentation
- Cynata Therapeutics Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline
- Offer Booklet and Entitlement & Acceptance Form
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics